Feed MKGAF
MK

MERCK Kommanditgesellschaft auf Aktien

MKGAF · OTC

$158.70 +1.57% (+$2.46)
1M +0.28%
Market Cap 61.5B €
P/E Ratio 25.92x
Div. Yield 1.62%
ROE 7.75%

Bulios Fair Price

$96.18

39.4% downside

Trenutna cena

$158.7

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica MKGAF trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Moderate
6/9
Valuation
64 /100
Fair
P/E 25.92x
EV/EBITDA 10.39x
P/S 2.91x
Growth
13 /100
Declining
EPS growth 7.78%
Rev. growth 1.74%
FCF growth 1.46%
Profitability
83 /100
Strong
Gross margin 58.70%
Net margin 11.22%
Op. margin 19.70%
Quality
38 /100
Average
ROIC 7.18%
ROE 7.75%
ROA 4.51%
Debt
82 /100
Low
Debt/Equity 0.41x
Current ratio 1.69x
Int. coverage 8.64x
Stability
100 /100
Stable
Beta 0.83x
Rev. volatility 3.40%
EPS volatility 6.80%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o MKGAF
Online

O podjetju

MERCK Kommanditgesellschaft is a German multinational pharmaceutical and chemical company headquartered in Darmstadt, founded in 1668. It is one of the oldest pharmaceutical and chemical companies in the world, operating in the fields of biotechnology, pharmaceuticals, and scientific and laboratory technologies. MERCK specializes in the development and manufacture of drugs, chemical compounds, and materials for scientific research. Its key areas of focus include immunotherapy, oncology, neurology, and reproductive health. MERCK is known for its innovation in scientific progress and the development of new therapeutic methods, with a strong global presence in over 70 countries.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Kai Beckmann

Employees

62,461

Headquarters

Darmstadt

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

37d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.